Abstract:BACKGROUND
CCR5 is the major coreceptor for human immunodeficiency virus (HIV). We investigated whether site-specific modification of the gene (“gene editing”) — in this case, the infusion of autologous CD4 T cells in which the CCR5 gene was rendered permanently dysfunctional by a zinc-finger nuclease (ZFN) — is safe.
METHODS
We enrolled 12 patients in an open-label, nonrandomized, uncontrolled study of a single dose of ZFN-modified autologous CD4 T cells. The patients had chronic aviremic HIV infection whil… Show more
“…Either gene-editing method could be used to generate further preclinical data. Ex vivo gene editing of CCR5 by NHEJ has been shown to be safe and effective in a phase I clinical trial, 44 whereas HDR is a newer technology that has not yet been tested clinically. However, HDR has a potential advantage in that it limits the number of possible integration events and may reduce the risk of insertional mutagenesis.…”
Section: Discussionmentioning
confidence: 99%
“…36,37 Individuals with an allelic variant that is not functional (CCR5D32) are protected from CCR5-tropic HIV infection. 38 Hematopoietic stem cell transplant using a CCR5D32 donor led to the only known cure of HIV-1 infection, 39,40 and T cells treated with engineered nucleases that introduce mutations at the CCR5 locus are resistant to HIV, [41][42][43][44][45] accelerating ongoing efforts to develop gene editing-and cell-based therapeutic agents for HIV. 11,46 Using new gene-editing techniques, it has recently become possible to achieve high rates of homology-directed recombination (HDR) of therapeutic cassettes into targeted loci, including CCR5 in primary T cells.…”
“…Either gene-editing method could be used to generate further preclinical data. Ex vivo gene editing of CCR5 by NHEJ has been shown to be safe and effective in a phase I clinical trial, 44 whereas HDR is a newer technology that has not yet been tested clinically. However, HDR has a potential advantage in that it limits the number of possible integration events and may reduce the risk of insertional mutagenesis.…”
Section: Discussionmentioning
confidence: 99%
“…36,37 Individuals with an allelic variant that is not functional (CCR5D32) are protected from CCR5-tropic HIV infection. 38 Hematopoietic stem cell transplant using a CCR5D32 donor led to the only known cure of HIV-1 infection, 39,40 and T cells treated with engineered nucleases that introduce mutations at the CCR5 locus are resistant to HIV, [41][42][43][44][45] accelerating ongoing efforts to develop gene editing-and cell-based therapeutic agents for HIV. 11,46 Using new gene-editing techniques, it has recently become possible to achieve high rates of homology-directed recombination (HDR) of therapeutic cassettes into targeted loci, including CCR5 in primary T cells.…”
“…In addition, inserting the stably expressed CRISPR/Cas9 system into a T-cell line conferred long-term protection against HIV-1 infection. With recent successful developments, gene-editing technologies have shown great promise in anti-HIV therapy for both preclinical studies and ongoing clinical trials [38][39][40] . As our data show, the system could work on physiologically relevant HIV-1 reservoir cell types and we expect that this system can be further exploited to develop alternative antiviral therapies in the future.…”
“…This consensus is most visible in western Europe, where 15 of 22 nations prohibit the modification of the germ line 4 . Although the United States has not officially prohibited germline modification, the US National Institutes of Health's Recombinant DNA Advisory Committee explicitly states that it "will not at present entertain proposals for germ line alterations" (see go.nature.com/mgscb2).…”
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.